National Heart and Lung Institute
13
2
2
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
15%
2 trials in Phase 3/4
13%
1 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Silicosis and Silicotuberculosis Among Small Scale Gemstone Miners in Northern Tanzania
Role: lead
AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer
Role: collaborator
Defining the Intestinal Microbiota in Premature Neonates
Role: collaborator
Monocentric Registry to Investigate the Role of Platelet Function, Platelet Genetics, Proteomics and Metabonomics in Heart Disease
Role: collaborator
The Use of Inflammatory Markers to Guide Therapy in Children With Severe Asthma
Role: collaborator
Cardiac Rehabilitation for the Treatment of Refractory Angina
Role: lead
The Impact of Cardiac Rehabilitation Participation on Cardiac Syndrome X
Role: lead
Secondary Prevention of coRonary Events After Discharge From Hospital (SPREAD)
Role: collaborator
Allopurinol in Chronic Heart Failure
Role: lead
Ursodeoxycholic Acid in Chronic Heart Failure
Role: lead
Enteral Nutrition in Congestive Heart Failure and Cardiac Cachexia
Role: lead
The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension
Role: collaborator
Effect of Intravenous Ferrous Sucrose on Exercise Capacity in Chronic Heart Failure
Role: lead
All 13 trials loaded